eISSN (Online): 2598-0580



Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

Screening and Identification of Erythrocyte Antibodies: A Narrative Literature Review

Yashinta Octavian Gita Setyanda[1], Zelly Dia Rofinda[2*]

[1]Clinical Pathology Resident, Department of Clinical Pathology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia

[2]Staff, Department of Clinical Pathology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia

ARTICLE INFO

Keywords:
Alloimmunization
Erythrocyte antibodies
Hemolytic disease
Laboratory techniques
Transfusion medicine

***Corresponding author:**
Zelly Dia Rofinda

E-mail address:
zellydiarofinda@med.unand.ac.id

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/bsm.v8i10.1091

A B S T R A C T

Red blood cell (RBC) alloimmunization, the development of antibodies against foreign red blood cell antigens, is a critical concern in transfusion medicine. Alloantibodies can lead to adverse transfusion reactions, including hemolytic disease of the fetus and newborn (HDFN) and delayed hemolytic transfusion reactions (DHTR). This comprehensive literature review explores the intricacies of RBC alloimmunization, focusing on the screening and identification of erythrocyte antibodies. We delve into the prevalence and clinical significance of various alloantibodies, the underlying immunological mechanisms, and the evolution of laboratory techniques for their detection. Additionally, we discuss the challenges and future directions in managing alloimmunization, emphasizing the importance of personalized medicine and innovative approaches to ensure safe and effective blood transfusions.

1. Introduction

Blood transfusion is a critical therapeutic intervention in modern medicine, saving countless lives and improving patient outcomes in various clinical scenarios. The ability to safely and effectively transfuse blood products relies on a thorough understanding of blood group systems and the potential for adverse immune reactions. Among these reactions, alloimmunization, the development of antibodies against foreign red blood cell (RBC) antigens, poses a significant challenge. Alloimmunization can lead to a range of complications, including hemolytic disease of the fetus and newborn (HDFN), delayed hemolytic transfusion reactions (DHTR), and transfusion-related acute lung injury (TRALI). The discovery of the ABO blood group system by Karl Landsteiner in 1900 marked a turning point in transfusion medicine. This groundbreaking discovery paved the way for safer transfusions by enabling the selection of compatible blood types based on the presence or absence of A and B antigens on the surface of RBCs. However, the complexity of the human RBC membrane extends far beyond the ABO system. Over 300 RBC antigens have been identified and organized into 36 blood group systems, each with the potential to trigger alloimmunization. Alloimmunization occurs when an individual is exposed to foreign RBC antigens, typically through transfusion, transplantation, or pregnancy. The recipient's immune system recognizes these antigens as non-self and mounts an immune

response, producing antibodies that can target and destroy the foreign RBCs. The clinical consequences of alloimmunization can be severe, ranging from mild febrile reactions to life-threatening hemolysis. The risk of alloimmunization varies depending on several factors, including the recipient's immune status, the immunogenicity of the foreign antigens, and the frequency of exposure. Patients requiring chronic transfusions, such as those with sickle cell disease or thalassemia, are at particularly high risk due to repeated exposure to foreign RBCs. Pregnant women are also at risk, as fetal RBCs carrying paternal antigens can cross the placenta and sensitize the maternal immune system.[1,2]

The prevention and management of alloimmunization are paramount in ensuring transfusion safety. This involves a multi-faceted approach, including careful donor selection, the use of leukoreduced blood products to minimize antigen exposure, and the implementation of effective antibody screening and identification protocols. Antibody screening is a critical step in the pre-transfusion testing process. It involves testing the recipient's plasma for the presence of antibodies that could react with donor RBCs. Several methods are available for antibody screening, including the tube method, gel method, and solid phase adherence method. Each method has its advantages and limitations, and the choice of method may depend on the laboratory's resources and expertise. Antibody identification is performed when a positive antibody screen is detected. This involves testing the recipient's plasma against a panel of RBCs with known antigen profiles to determine the specificity of the antibodies present. Accurate antibody identification is essential for selecting compatible blood products and preventing adverse transfusion reactions. Recent advances in laboratory techniques have significantly improved the sensitivity and specificity of antibody screening and identification. The development of automated platforms and the use of monoclonal antibodies have streamlined the testing process and reduced the risk of human error. However, challenges remain, particularly in identifying rare or complex antibody specificities. The management of patients with alloantibodies requires a personalized approach. This involves careful consideration of the patient's clinical history, transfusion history, and antibody profile. In some cases, it may be necessary to transfuse antigen-negative blood products, which are RBCs that lack the specific antigen targeted by the patient's antibodies. However, finding compatible antigen-negative blood can be challenging, especially for patients with multiple alloantibodies.[3,4]

Prevalence of red blood cell alloimmunization

The prevalence of red blood cell (RBC) alloimmunization, a condition where individuals develop antibodies against foreign RBC antigens, is not uniform across populations. It is influenced by a multitude of factors, including the specific patient population, their transfusion history, and their ethnicity. In the general population, where individuals have not been exposed to foreign RBC antigens through transfusion or pregnancy, the prevalence of alloimmunization is relatively low. Studies have estimated this rate to be between 0.5% and 1.5%. This suggests that a small percentage of individuals naturally possess antibodies against RBC antigens they have never encountered, possibly due to exposure to similar antigens in the environment or through cross-reactivity with other substances. However, the prevalence of alloimmunization rises significantly in specific patient populations, particularly those with chronic transfusion needs. Individuals with conditions like sickle cell disease (SCD) and thalassemia often require frequent blood transfusions throughout their lives. Each transfusion exposes them to a variety of RBC antigens, increasing the likelihood of alloimmunization. Studies have reported alloimmunization rates in these patient populations ranging from 14% to a staggering 50%. This high prevalence is a major concern, as alloantibodies can lead to complications such as delayed hemolytic transfusion reactions (DHTR) and difficulty in finding compatible blood for future transfusions. Ethnicity

also plays a role in alloimmunization rates. Certain blood group antigens are more prevalent in specific ethnic groups. For example, the Duffy blood group antigens Fya and Fyb are less common in individuals of African descent. This difference in antigen prevalence can influence the likelihood of alloimmunization when individuals from different ethnic backgrounds receive blood transfusions.[5,6]

Clinical significance of alloantibodies

The clinical significance of alloantibodies is not solely determined by their presence but also by their specificity and titer (concentration). Some alloantibodies are notorious for their ability to trigger severe adverse reactions, while others are considered less clinically relevant. One of the most clinically significant alloantibodies is anti-D. This antibody targets the RhD antigen, which is present on the surface of RBCs in Rh-positive individuals. Anti-D is highly immunogenic, meaning it can readily stimulate an immune response in Rh-negative individuals who are exposed to Rh-positive blood. The consequences of anti-D alloimmunization can be severe, leading to hemolytic disease of the fetus and newborn (HDFN) in pregnant women and DHTR in transfusion recipients. Anti-K is another highly immunogenic alloantibody that can cause severe hemolytic reactions. It targets the Kell antigen, which is also found on the surface of RBCs. Anti-K-mediated hemolysis can occur rapidly and can be life-threatening. Anti-c and anti-E, while less immunogenic than anti-D, can still cause HDFN and DHTR. These antibodies target the Rhc and Rhe antigens, respectively, which are part of the Rh blood group system. Although less common than anti-D, they are still important to consider in transfusion practice. The Duffy blood group system also harbors clinically significant alloantibodies. Anti-Fya and anti-Fyb are associated with delayed hemolytic transfusion reactions, which can occur days or even weeks after a transfusion. These reactions may be less severe than acute hemolytic reactions but can still lead to significant morbidity. The Kidd blood group system is home to anti-Jka and anti-Jkb, which can cause both acute and delayed hemolytic transfusion reactions. These antibodies are known for their ability to cause severe hemolysis, and their detection is crucial for preventing adverse transfusion outcomes. While the alloantibodies mentioned above are considered clinically significant due to their potential to cause hemolytic reactions, other alloantibodies, such as anti-M and anti-N, are generally considered less significant. These antibodies rarely cause hemolysis but can still interfere with laboratory testing and complicate the selection of compatible blood products. Their presence may necessitate additional testing and careful consideration when choosing blood for transfusion (Table 1).[7-9]

Table 1. Clinical significance of alloantibodies.

Blood group system	Antigen structure	Antibody	Clinical significance
ABO	Carbohydrate	Anti-A, Anti-B	Hemolytic transfusion reaction, Hemolytic disease of the fetus and newborn (HDFN) (mild)
Rh	Protein	Anti-D, -C, -c, -E, -e	Hemolytic transfusion reaction, HDFN
Kell	Protein	Anti-K	Hemolytic transfusion reaction, HDFN
Kidd	Protein	Anti-Jka, -Jkb	Hemolytic transfusion reaction, HDFN (rare)
Duffy	Glycoprotein	Anti-Fya, -Fyb	Hemolytic transfusion reaction, HDFN
MNS	Glycoprotein	Anti-M, -N, -S, -s	Hemolytic transfusion reaction (rare), HDFN (rare)
P	Carbohydrate	Anti-P1	Hemolytic transfusion reaction (rare), Not associated with HDFN
Lewis	Carbohydrate	Anti-Lea, -Leb	Hemolytic transfusion reaction (rare), Not associated with HDFN
I	Carbohydrate	Autoanti-I	Not associated with hemolytic transfusion reaction, Not associated with HDFN (except in rare cases of autoimmune hemolytic anemia)

Immunological mechanisms of alloimmunization

Alloimmunization, the development of antibodies against foreign red blood cell (RBC) antigens, is a complex immunological process with significant implications for transfusion medicine. This intricate process involves a series of events that culminate in the production of antibodies capable of targeting and destroying transfused RBCs, potentially leading to adverse transfusion reactions and hemolytic disease of the fetus and newborn (HDFN). The first step in alloimmunization is the recognition of foreign RBC antigens by the recipient's immune system. These antigens, which are proteins, glycoproteins, or glycolipids on the surface of RBCs, are genetically determined and vary among individuals. When an individual is exposed to RBCs with foreign antigens, typically through transfusion, transplantation, or pregnancy, their immune system recognizes these antigens as non-self. Antigen-presenting cells (APCs), such as dendritic cells and macrophages, play a crucial role in this process. APCs capture and process the foreign RBC antigens, breaking them down into smaller peptides. These peptides are then presented on the surface of APCs in conjunction with major histocompatibility complex (MHC) molecules. The type of MHC molecule involved depends on the type of antigen and the type of immune response elicited. The presentation of foreign RBC antigens by APCs activates a specific type of white blood cell called a B cell. B cells have specialized receptors on their surface, known as B cell receptors (BCRs), that can recognize and bind to specific antigens. When a BCR binds to its cognate antigen, the B cell becomes activated. Activated B cells undergo a process of clonal expansion, rapidly dividing and differentiating into two main types of cells: plasma cells and memory B cells. Plasma cells are short-lived factories that produce and secrete large quantities of antibodies specific to the foreign RBC antigen. Memory B cells, on the other hand, are long-lived cells that remain in circulation, providing immunological memory and enabling a faster and more robust immune response upon subsequent exposure to the same antigen.[10-12]

The antibodies produced by plasma cells are proteins that can bind to specific antigens on the surface of RBCs. The binding of antibodies to RBC antigens can trigger a variety of effector functions, including: 1. Agglutination: Antibodies can cross-link multiple RBCs, causing them to clump together. This agglutination can lead to the destruction of the RBCs by the immune system. 2. Opsonization: Antibodies can coat the surface of RBCs, making them more recognizable and susceptible to phagocytosis by immune cells. 3. Complement activation: Antibodies can activate the complement system, a cascade of proteins that can lead to the formation of membrane attack complexes (MACs) on the surface of RBCs. MACs can cause holes in the RBC membrane, leading to cell lysis and hemolysis. Several factors can influence the likelihood and severity of alloimmunization. These factors can be broadly categorized into host factors, antigen factors, and environmental factors. Individuals with compromised immune systems, such as those with HIV/AIDS or undergoing immunosuppressive therapy, may be less likely to develop alloantibodies. However, they may also be more susceptible to severe complications if alloimmunization does occur. Certain genetic predispositions, such as variations in HLA genes, may increase the risk of alloimmunization. Younger individuals and women of childbearing age may be at higher risk of alloimmunization due to increased exposure to foreign RBC antigens through transfusion and pregnancy. The immunogenicity of an antigen refers to its ability to elicit an immune response. Some RBC antigens are more immunogenic than others, meaning they are more likely to trigger alloimmunization. The amount of foreign antigen exposure can affect the likelihood of alloimmunization. Larger doses of antigen are more likely to trigger an immune response. The way in which an antigen is presented to the immune system can influence the type and magnitude of the immune response. The number and type of transfusions an individual has received can significantly impact their risk of alloimmunization. Women who have been pregnant

are at increased risk of alloimmunization due to exposure to fetal RBC antigens. Other factors, such as concomitant infections or medications, may also influence the risk of alloimmunization. Alloimmunization is a complex immunological process with significant implications for transfusion medicine. Understanding the mechanisms underlying alloimmunization is crucial for developing effective strategies to prevent and manage this complication. By identifying individuals at risk of alloimmunization and implementing appropriate interventions, we can ensure the safe and effective transfusion of blood products and improve patient outcomes (Table 2).[13-16]

Table 2. Immunological mechanisms of alloimmunization.

Step	Process	Key players	Outcome
1	Antigen Recognition and Presentation	Antigen-presenting cells (APCs)	Foreign RBC antigens are recognized and processed by APCs, then presented on their surface with MHC molecules.
2	B Cell Activation and Differentiation	B cells, B cell receptors (BCRs)	B cells with BCRs specific to the foreign antigen are activated and undergo clonal expansion, differentiating into plasma cells and memory B cells.
3	Antibody Production and Effector Functions	Plasma cells, antibodies (IgM and IgG)	Plasma cells secrete antibodies that bind to foreign RBC antigens, leading to agglutination, opsonization, and complement activation.
4	Factors Influencing Alloimmunization	Host factors (immune status, genetics, age, sex), antigen factors (immunogenicity, dose, presentation), environmental factors (transfusion history, pregnancy history)	The likelihood and severity of alloimmunization are influenced by various host, antigen, and environmental factors.

Laboratory techniques for antibody screening and identification

The laboratory detection and identification of erythrocyte antibodies are pivotal in transfusion medicine, serving as a cornerstone for ensuring transfusion safety and preventing adverse reactions. Over the years, a variety of techniques have been developed and refined, each with its own strengths and limitations. These techniques have evolved from traditional manual methods to sophisticated automated platforms, enhancing the accuracy, efficiency, and sensitivity of antibody detection.[17,18]

Tube method (conventional technique)

The tube method, also referred to as the conventional technique, is the cornerstone of antibody screening and identification in transfusion medicine. It is the oldest and most fundamental method, serving as the basis for subsequent advancements in laboratory techniques. Despite its simplicity, the tube method remains a valuable tool in many laboratories, particularly those with limited resources. The tube method operates on the principle of hemagglutination, the clumping together of red blood cells (RBCs) in the presence of specific antibodies. In this method, patient serum or plasma is mixed with RBCs of known antigenicity in test tubes. The mixture is then incubated at various temperatures, typically including room temperature (20-24°C), 37°C (body temperature), and after the addition of enhancement reagents. The incubation at different temperatures allows for the detection of both warm-reactive (IgG) and cold-reactive (IgM) antibodies. Warm-reactive antibodies typically bind to RBC antigens at 37°C, while cold-reactive antibodies bind at lower temperatures. The addition of enhancement reagents, such as low ionic strength solution (LISS) or polyethylene glycol (PEG), can increase the sensitivity of the test by promoting antibody-antigen interactions. Following incubation, the tubes are centrifuged to bring the RBCs together.

The RBCs are then examined for agglutination or hemolysis, which are indicative of the presence of antibodies in the patient's serum or plasma. Agglutination appears as visible clumping of RBCs, while hemolysis is characterized by the release of hemoglobin from the RBCs, resulting in a pink or red discoloration of the supernatant.[19,20]

Preparation of Reagents and Samples: 1. Reagent Red Blood Cells (RBCs): A 2-5% suspension of RBCs with known antigens is prepared. These RBCs are typically obtained from commercial sources and are selected to represent a wide range of clinically significant blood group antigens. 2. Patient Serum or Plasma: The patient's serum or plasma is obtained, which contains the antibodies to be detected. Plasma is preferred over serum as it avoids the potential interference of fibrinogen in the agglutination reaction. Immediate Spin (IS) Phase: 1. Mixing: One drop of patient serum or plasma is mixed with one drop of reagent RBCs in a labeled test tube. 2. Centrifugation: The tube is centrifuged at low speed (1000-1500 rpm) for a short duration (15-30 seconds). 3. Observation: The tube is examined for agglutination (clumping of RBCs) or hemolysis (rupture of RBCs). Agglutination or hemolysis at this stage indicates the presence of cold-reactive antibodies (IgM) that bind to RBC antigens at room temperature. 37°C Incubation Phase: 1. Incubation: If the IS phase is negative, the tube is incubated at 37°C for 30-60 minutes. This allows warm-reactive antibodies (IgG) to bind to RBC antigens at body temperature. 2. Centrifugation and Observation: The tube is centrifuged again, and the RBCs are examined for agglutination or hemolysis. A positive reaction at this stage suggests the presence of warm-reactive antibodies. Enhancement Phase (Optional): 1. Addition of Enhancement Reagent: If the 37°C incubation phase is negative, an enhancement reagent, such as low ionic strength solution (LISS) or polyethylene glycol (PEG), is added to the tube. These reagents enhance antibody-antigen interactions by reducing the ionic strength of the reaction medium or concentrating the antibodies, respectively. 2. Incubation and Centrifugation: The tube is incubated again at 37°C for 15-30 minutes and then centrifuged. 3. Observation: The RBCs are examined for agglutination or hemolysis. A positive reaction at this stage indicates the presence of antibodies that require enhancement for detection. Antiglobulin Test (AGT) Phase: 1. Washing: If the enhancement phase is negative, the RBCs are washed three to four times with saline to remove any unbound antibodies. 2. Addition of AHG Reagent: Two drops of anti-human globulin (AHG) reagent, also known as Coombs' reagent, are added to the tube. AHG reagent contains antibodies that bind to human IgG or complement proteins attached to the surface of RBCs. 3. Centrifugation and Observation: The tube is centrifuged, and the RBCs are examined for agglutination or hemolysis. A positive reaction at this stage indicates the presence of IgG antibodies or complement proteins on the surface of RBCs, suggesting the presence of clinically significant antibodies. Interpretation of Results: 1. Grading of Agglutination: The agglutination reactions are graded on a scale of 0 (negative) to 4+ (strongly positive) based on the size and strength of the agglutinates. 2. Hemolysis: Hemolysis is considered a positive reaction, indicating the presence of antibodies that can cause RBC destruction. 3. Coombs' Control Cells (CCCs): If the AGT phase is negative, Coombs' control cells (CCCs) are added to the tube. CCCs are RBCs coated with IgG antibodies, and their agglutination confirms the validity of the AHG reagent and the washing steps. The tube method, while relatively simple, requires meticulous attention to detail and adherence to standardized procedures to ensure accurate and reliable results. It is essential to use appropriate controls, maintain proper incubation temperatures, and carefully interpret the observed reactions to avoid false-positive or false-negative results.[20,21]

The tube method is relatively simple to perform and does not require specialized equipment, making it accessible to laboratories with limited resources. It is a cost-effective method, as the reagents and consumables are relatively inexpensive. The tube method can be adapted to detect a wide range of

antibodies, including both warm-reactive (IgG) and cold-reactive (IgM) antibodies. This flexibility allows for the customization of the test based on the specific clinical scenario and suspected antibodies. The tube method provides a valuable educational tool for understanding the principles of hemagglutination and antibody-antigen interactions. It allows for direct observation of agglutination and hemolysis reactions, which can aid in the interpretation of results and troubleshooting of technical issues. The interpretation of results can be subjective, as it relies on visual observation of agglutination or hemolysis. The degree of agglutination can vary among technicians, leading to potential inconsistencies in interpretation. The tube method is labor-intensive and time-consuming, requiring multiple washing steps, manual observation, and grading of reactions. This can limit the throughput of the test and increase the risk of human error. Compared to newer methods, the tube method may have lower sensitivity, particularly for detecting weak or low-titer antibodies. This can lead to false-negative results, potentially missing clinically significant antibodies. The tube method involves the handling of blood samples and reagents, which poses a risk of exposure to bloodborne pathogens. Proper safety precautions, such as the use of personal protective equipment and adherence to biosafety protocols, are essential to minimize this risk. Despite its limitations, the tube method remains a valuable tool in transfusion medicine. It is commonly used in resource-limited settings where access to more advanced technologies may be limited. Additionally, the tube method is often used as a confirmatory test for positive results obtained using other methods, such as the gel or solid phase adherence methods.

In conclusion, the tube method is a fundamental technique for antibody screening and identification in transfusion medicine. While it has some limitations, its simplicity, cost-effectiveness, and flexibility make it a valuable tool in many laboratories. As technology continues to advance, the tube method may be gradually replaced by newer, more automated methods. However, it is likely to remain an important part of the transfusion medicine laboratory for the foreseeable future.[21,22]

Gel method (column agglutination technology)

The gel method, also known as column agglutination technology, represents a significant advancement in the field of erythrocyte antibody screening and identification. This technique offers enhanced sensitivity, specificity, and standardized interpretation compared to the traditional tube method, making it a valuable tool in modern transfusion medicine laboratories. The gel method is based on the principle of differential migration of red blood cells (RBCs) through a microtube filled with a dextran acrylamide gel matrix. The gel matrix acts as a sieve, allowing non-agglutinated RBCs to pass through and form a pellet at the bottom of the tube while trapping agglutinated RBCs within the gel. The gel card, a plastic card containing multiple microtubes, is the primary component of the gel method. Each microtube is pre-filled with a specific gel, and the gel's properties, such as its density and pore size, can be tailored to optimize the detection of different types of antibodies. The patient's serum or plasma is mixed with reagent RBCs and added to the top of the microtube. During centrifugation, the RBCs migrate through the gel matrix. If antibodies are present in the patient's sample that bind to antigens on the reagent RBCs, agglutination occurs. The agglutinated RBCs, being larger and heavier, are trapped within the gel matrix at varying levels depending on the size of the agglutinates. Non-agglutinated RBCs, on the other hand, pass through the gel and form a pellet at the bottom of the microtube.[23,24]

Preparation of Reagents and Samples: 1. Gel Card: Select the appropriate gel card based on the type of antibody screening or identification being performed. Different gel cards may be used for detecting IgG antibodies, IgM antibodies, or both. 2. Reagent RBCs: Prepare a 0.8% suspension of reagent RBCs in a low ionic strength solution (LISS). LISS enhances antibody-antigen interactions by reducing the ionic

strength of the reaction medium. 3. Patient Serum or Plasma: Obtain the patient's serum or plasma, which contains the antibodies to be detected. Sample and Reagent Dispensing: 1. Pipetting: Using a micropipette, dispense the specified volume of patient serum or plasma and reagent RBCs into the appropriate microtubes on the gel card. 2. Mixing: Gently mix the contents of the microtubes by tapping the card or using a mechanical mixer. Incubation: Incubate the gel card at 37°C for a specified duration, typically 15-60 minutes, depending on the type of antibodies being detected. This allows for optimal antibody-antigen binding. Centrifugation: Centrifuge the gel card at a specific speed and time, typically 1000-1500 rpm for 10 minutes. This forces the RBCs to migrate through the gel matrix, separating agglutinated RBCs from non-agglutinated RBCs. Interpretation of Results: 1. Visual Assessment: Visually examine the gel card for agglutination reactions. Agglutinated RBCs will be trapped within the gel at different levels, while non-agglutinated RBCs will form a pellet at the bottom of the microtube. 2. Grading of Reactions: Grade the agglutination reactions on a scale of 0 (negative) to 4+ (strong positive) based on the position and intensity of the agglutinates within the gel column. 3. Mixed-Field Reactions: In some cases, a mixed-field reaction may be observed, where both agglutinated and non-agglutinated RBCs are present. This can occur when the patient has antibodies against multiple antigens or when the antibody titer is low.[24,25]

The gel method is generally more sensitive and specific than the tube method due to several factors. The gel matrix concentrates the RBCs, increasing the likelihood of antibody-antigen interactions. Additionally, the gel acts as a filter, removing unbound antibodies and other interfering substances, leading to clearer and more easily interpretable results. The gel method provides a more standardized interpretation of results compared to the tube method. The agglutination reactions are graded based on the position of the RBCs within the gel column, allowing for a more objective and consistent assessment of antibody strength. The gel method requires fewer washing steps and less manual manipulation than the tube method, reducing hands-on time for laboratory personnel. This can improve laboratory efficiency and reduce the risk of human error. The gel method minimizes the risk of exposure to bloodborne pathogens as it involves less direct handling of blood samples and reagents compared to the tube method. The gel matrix provides a clear background for visualizing agglutination reactions, making it easier to detect weak or mixed-field reactions. The agglutination reactions in the gel method are stable for up to 24 hours, allowing for later review and documentation of results. The gel method is more expensive than the tube method due to the need for specialized gel cards, equipment, and reagents. This can be a limiting factor for laboratories with budget constraints. The gel method may not be suitable for detecting all types of antibodies, particularly those that require specific enhancement reagents or incubation conditions not compatible with the gel matrix. While the gel method is relatively simple to perform, it requires some technical expertise to ensure proper sample and reagent dispensing, centrifugation, and interpretation of results. In some cases, the gel method may produce false-positive reactions due to non-specific agglutination or interference from other substances in the sample. The gel method is commonly used for routine antibody screening in both blood donors and transfusion recipients. It can detect a wide range of clinically significant antibodies, including those directed against Rh, Kell, Duffy, Kidd, and other blood group antigens. The gel method can also be used for antibody identification, using panels of reagent RBCs with known antigen profiles. This helps to determine the specificity of the antibodies present in the patient's sample. In some cases, the gel method can be used for crossmatching, which involves testing the compatibility of donor RBCs with the recipient's plasma. However, the tube method is still considered the gold standard for crossmatching. The gel method has revolutionized the field of erythrocyte antibody screening and identification, offering numerous

advantages over the traditional tube method. Its enhanced sensitivity, specificity, standardized interpretation, and reduced hands-on time have made it a valuable tool in modern transfusion medicine laboratories. While it has some limitations, the gel method continues to evolve, with ongoing research and development aimed at further improving its performance and expanding its applications. As technology advances, the gel method is likely to play an increasingly important role in ensuring transfusion safety and improving patient care.[25,26]

Solid phase adherence method (microplate technology)

The solid phase adherence (SPA) method, also known as microplate technology or enzyme-linked immunosorbent assay (ELISA)-based technology, is a highly sensitive and specific technique for erythrocyte antibody screening and identification. This method has gained prominence in transfusion medicine due to its ability to detect even weak or low-titer antibodies, which may be missed by traditional tube or gel methods. The SPA method's adaptability to automation further enhances its efficiency and throughput, making it a valuable tool in modern blood banks and transfusion services. The SPA method is based on the principle of antibody-antigen binding on a solid support, typically a microplate well. The wells of the microplate are coated with purified red blood cell (RBC) antigens, either individually or in combination, depending on the specific test being performed. Patient serum or plasma is then added to the wells, and any antibodies present in the sample will bind to their corresponding antigens on the well surface. After incubation, the wells are washed to remove any unbound antibodies. Indicator RBCs coated with anti-human IgG (anti-IgG) are then added to the wells. If antibodies are bound to the antigens in the well, the anti-IgG on the indicator RBCs will bind to the Fc portion of the antibodies, forming a sandwich complex. This complex results in the agglutination of the indicator RBCs, which can be visualized as a diffuse pattern on the well surface. In the absence of antibodies, the indicator RBCs will not agglutinate and will settle to the bottom of the well, forming a button.[26]

Preparation of Reagents and Samples: 1. Microplate: Select the appropriate microplate based on the type of antibody screening or identification being performed. Different microplates may be coated with different combinations of RBC antigens. 2. Patient Serum or Plasma: Obtain the patient's serum or plasma, which contains the antibodies to be detected. 3. Indicator RBCs: Prepare a suspension of indicator RBCs coated with anti-IgG. 4. Wash Solution: Prepare a wash solution, typically phosphate-buffered saline (PBS) or a similar buffer, to remove unbound antibodies. Sample and Reagent Dispensing: 1. Pipetting: Using a micropipette, dispense the specified volume of patient serum or plasma into the appropriate wells of the microplate. 2. Incubation: Incubate the microplate at 37°C for a specified duration, typically 15-30 minutes, to allow for antibody-antigen binding. Washing: 1. Aspiration: Aspirate the contents of the wells using a microplate washer or a manual aspirator. 2. Washing: Wash the wells multiple times (usually 3-4 times) with the wash solution to remove unbound antibodies. Addition of Indicator RBCs: 1. Dispensing: Dispense the specified volume of indicator RBCs into each well. 2. Centrifugation: Centrifuge the microplate at a low speed (1000-1500 rpm) for a short duration (1-2 minutes) to bring the indicator RBCs into contact with the bound antibodies. Interpretation of Results: 1. Visual Assessment: Visually examine the microplate for agglutination reactions. A positive reaction will appear as a diffuse pattern of agglutinated indicator RBCs covering the well surface. A negative reaction will appear as a button of non-agglutinated RBCs at the bottom of the well. 2. Automated Reading (Optional): For higher throughput and objectivity, the microplate can be read using a spectrophotometer or other automated reader. The absorbance values are then compared to a cutoff value to determine the presence or absence of antibodies.[26,27]

The SPA method is renowned for its high sensitivity and specificity, making it the preferred method for

detecting weak or low-titer antibodies that may be missed by other techniques. This is particularly important in identifying clinically significant antibodies that could cause delayed hemolytic transfusion reactions or HDFN. The SPA method is readily adaptable to automation, allowing for high-throughput screening and identification of antibodies. Automated platforms can handle large numbers of samples, reducing hands-on time for laboratory personnel and minimizing the risk of human error. The results of the SPA method can be interpreted objectively using automated readers, eliminating the subjectivity associated with visual assessment of agglutination reactions. This ensures consistency and reproducibility of results across different laboratories and technicians. The SPA method minimizes the risk of exposure to bloodborne pathogens as it involves minimal direct handling of blood samples and reagents. The SPA method can be adapted to detect a wide range of antibodies, including both warm-reactive (IgG) and cold-reactive (IgM) antibodies. Different microplates can be coated with specific antigens or combinations of antigens to tailor the test to the specific clinical scenario. The SPA method is the most expensive of the three main methods (tube, gel, and SPA) due to the need for specialized microplates, equipment, and reagents. This can be a significant barrier for resource-limited laboratories. The SPA method can be more complex to perform and interpret compared to the tube and gel methods. It requires technical expertise in handling microplates, pipetting small volumes, and operating automated readers. The SPA method may occasionally produce false-positive reactions due to non-specific binding of antibodies or other interfering substances in the sample. Careful washing steps and the use of appropriate controls are essential to minimize this risk. The SPA method is increasingly used for routine antibody screening in blood donors and transfusion recipients due to its high sensitivity and specificity. The SPA method is the gold standard for antibody identification, allowing for the precise determination of antibody specificity using panels of reagent RBCs with known antigen profiles. The SPA method is particularly useful in investigating complex antibody reactions, such as those involving multiple antibodies or antibodies with low titers. The SPA method is also used in research and development settings to study the characteristics of RBC antigens and antibodies, develop new diagnostic tests, and evaluate the efficacy of therapeutic interventions. The solid phase adherence method has revolutionized the field of erythrocyte antibody screening and identification, offering unparalleled sensitivity, specificity, and automation capabilities. While it has some limitations, its advantages have made it an indispensable tool in modern transfusion medicine laboratories. As technology continues to advance, the SPA method is likely to evolve further, with the development of new microplates, reagents, and automated platforms that will further enhance its performance and expand its applications. The SPA method's ability to detect even weak or low-titer antibodies is crucial for ensuring transfusion safety and preventing adverse reactions, ultimately improving patient care and outcomes.[26,27]

Microarray technology

Microarray technology is an innovative and high-throughput approach that has revolutionized the field of erythrocyte antibody screening and identification. This cutting-edge technology utilizes microarrays, which are solid surfaces containing a vast number of immobilized red blood cell (RBC) antigens. These microarrays enable the simultaneous screening for multiple antibodies in a single assay, offering significant advantages over traditional methods in terms of speed, efficiency, and comprehensiveness. The fundamental principle behind microarray technology lies in the specific interaction between antibodies and their corresponding antigens. In the context of erythrocyte antibody screening, microarrays are designed to contain a diverse array of RBC antigens, representing various blood group systems and specificities. These antigens are immobilized on the microarray surface in a highly organized and addressable manner, allowing for the precise

identification of bound antibodies. When a patient's serum or plasma sample is applied to the microarray, any antibodies present in the sample will bind to their specific target antigens on the microarray surface. This binding event can be detected and quantified using various detection methods, such as fluorescence or chemiluminescence. The resulting signal pattern provides a comprehensive profile of the antibodies present in the sample, enabling the identification of both common and rare alloantibodies.[27]

Procedure of Microarray Technology: 1. Microarray Preparation: The first step involves the preparation of the microarray slide. This typically involves spotting or printing purified RBC antigens onto a solid surface, such as glass or silicon. The antigens are carefully selected to represent a wide range of clinically significant blood group systems and specificities. 2. Sample Preparation: The patient's serum or plasma sample is prepared for analysis. This may involve dilution, filtration, or other pre-treatment steps to optimize the assay performance. 3. Hybridization: The prepared sample is applied to the microarray slide and incubated under controlled conditions to allow for antibody-antigen binding. The incubation time and temperature may vary depending on the specific microarray platform and the type of antibodies being detected. 4. Washing: After incubation, the microarray slide is washed to remove any unbound antibodies or other non-specific binding components. 5. Detection: The bound antibodies are detected using a suitable detection method. This typically involves the use of labeled secondary antibodies or other probes that specifically bind to the Fc portion of the primary antibodies. The labels can be fluorescent molecules, enzymes, or other detectable markers. 6. Signal Amplification (Optional): In some cases, signal amplification steps may be employed to enhance the sensitivity of the assay. This can be achieved using various techniques, such as enzyme-linked immunosorbent assay (ELISA) or rolling circle amplification (RCA). 7. Data Acquisition and Analysis: The signals generated by the bound antibodies are captured using a microarray scanner or other imaging device. The resulting data is then analyzed using specialized software to identify the specific antibodies present in the sample and determine their relative strengths.[28]

Microarray technology enables the simultaneous screening for a large number of antibodies in a single assay, significantly increasing throughput compared to traditional methods that require individual testing for each antibody specificity. Microarrays can detect even weak or low-titer antibodies due to the high density of antigens on the microarray surface and the use of sensitive detection methods. This is crucial for identifying clinically significant antibodies that may be missed by other techniques. Microarrays provide a comprehensive profile of the antibodies present in a patient's sample, including both common and rare specificities. This information is valuable for selecting compatible blood products and managing patients with complex antibody profiles. Microarray technology is amenable to automation, reducing hands-on time for laboratory personnel and minimizing the risk of human error. Automated platforms can handle large numbers of samples, increasing efficiency and reducing turnaround time. The use of automated readers and standardized data analysis software ensures objective and consistent interpretation of results, reducing inter-laboratory variability. While the initial investment in microarray equipment and reagents may be high, the cost per test can be lower than traditional methods due to the high throughput and reduced labor costs. The initial investment in microarray equipment and reagents can be substantial, making it less accessible to resource-limited laboratories. Microarray technology requires specialized equipment, reagents, and expertise for proper implementation and interpretation of results. The availability of purified RBC antigens for microarray fabrication can be limited, particularly for rare or less common specificities. Non-specific binding of antibodies or other interfering substances can lead to false-positive reactions. Careful optimization of assay conditions and the use of appropriate controls are essential to minimize this risk. Microarrays are

increasingly used for routine antibody screening and identification in blood donors and transfusion recipients. They offer a comprehensive and efficient approach to detect a wide range of clinically significant antibodies. Microarrays can be used to monitor the development and progression of alloimmunization in patients receiving chronic transfusions or undergoing transplantation. Microarray technology is a valuable tool for research and development in transfusion medicine. It can be used to study the characteristics of RBC antigens and antibodies, develop new diagnostic tests, and evaluate the efficacy of therapeutic interventions. Microarray technology has emerged as a powerful tool in the field of erythrocyte antibody screening and identification. Its high throughput, enhanced sensitivity, comprehensive antibody profiling, and automation capabilities have revolutionized the way we detect and manage alloantibodies. While challenges remain, ongoing research and development are expected to further refine this technology and expand its applications, ultimately improving transfusion safety and patient care.[27,28]

Bead-based assays

Bead-based assays have emerged as a powerful tool in the realm of erythrocyte antibody screening and identification, offering a versatile and efficient platform for detecting and characterizing antibodies in a flow cytometry-based format. This innovative technology utilizes microbeads coated with specific red blood cell (RBC) antigens to capture and identify corresponding antibodies present in patient serum or plasma samples. The flexibility, sensitivity, and high-throughput capabilities of bead-based assays have made them an attractive alternative to traditional methods, particularly in the context of complex antibody investigations and large-scale screening programs. The underlying principle of bead-based assays is the specific interaction between antibodies and their cognate antigens. In this context, microbeads, typically made of polystyrene or silica, are coated with purified RBC antigens representing various blood group systems and specificities. These antigen-coated beads serve as capture probes for antibodies present in the sample. When a patient's serum or plasma is incubated with the antigen-coated beads, any antibodies specific to the antigens on the beads will bind, forming an antibody-antigen complex. The beads are then washed to remove unbound antibodies and incubated with a fluorescently labeled secondary antibody that recognizes the Fc portion of the primary antibody. This secondary antibody binds to the primary antibody, forming a sandwich complex that can be detected and quantified using flow cytometry. Flow cytometry is a powerful technique that allows for the rapid analysis of individual cells or particles in a fluid stream. In the case of bead-based assays, the flow cytometer measures the fluorescence intensity of each bead, which is directly proportional to the amount of antibody bound to the bead. This enables the identification and quantification of multiple antibodies simultaneously, providing a comprehensive profile of the patient's antibody repertoire.[29]

Procedure of Bead-Based Assays: 1. Bead Preparation: Microbeads are coated with purified RBC antigens representing various blood group systems and specificities. The beads are typically dyed with different fluorescent dyes to allow for multiplexing, where multiple antigens can be tested simultaneously. 2. Sample Preparation: Patient serum or plasma is diluted and incubated with the antigen-coated beads. The incubation time and temperature may vary depending on the specific assay kit and the type of antibodies being detected. 3. Washing: After incubation, the beads are washed to remove unbound antibodies and other non-specific binding components. 4. Secondary Antibody Incubation: The beads are incubated with a fluorescently labeled secondary antibody that recognizes the Fc portion of the primary antibody. 5. Flow Cytometry Analysis: The beads are analyzed using a flow cytometer. The flow cytometer measures the fluorescence intensity of each bead, which is proportional to the amount of antibody bound to the bead. The data is then analyzed using

specialized software to identify the specific antibodies present in the sample and determine their relative strengths.[30]

Bead-based assays allow for the simultaneous detection of multiple antibodies in a single reaction, significantly increasing throughput and reducing the amount of sample required. This is particularly advantageous when screening for a large panel of antibodies or when investigating complex antibody profiles. The use of flow cytometry for detection enables the quantification of even low levels of antibodies, enhancing the sensitivity of the assay. This is crucial for identifying clinically significant antibodies that may be missed by less sensitive methods. Bead-based assays can be easily customized to include a wide range of RBC antigens, allowing for the detection of both common and rare antibodies. The flexibility of the platform also allows for the development of assays tailored to specific clinical needs, such as screening for antibodies in specific patient populations or monitoring the response to treatment. Bead-based assays are readily adaptable to automation, reducing hands-on time for laboratory personnel and minimizing the risk of human error. Automated platforms can handle large numbers of samples, increasing efficiency and reducing turnaround time. Flow cytometry provides quantitative data on the amount of antibody bound to each bead, allowing for a more precise assessment of antibody titers. This information can be valuable for monitoring the progression of alloimmunization and assessing the effectiveness of therapeutic interventions. The use of flow cytometry and standardized data analysis software ensures objective and consistent interpretation of results, reducing inter-laboratory variability. Bead-based assays can be more expensive than traditional methods due to the need for specialized equipment, reagents, and flow cytometry analysis. However, the cost per test can be lower when multiplexing is employed, as multiple antibodies can be tested simultaneously. Bead-based assays require technical expertise in flow cytometry and data analysis. Proper training and quality control measures are essential to ensure accurate and reliable results. The availability of purified RBC antigens for bead coating can be limited, particularly for rare or less common specificities. This can restrict the range of antibodies that can be detected using this method. Certain substances in patient samples, such as lipemia or hemolysis, can interfere with the assay and lead to inaccurate results. Proper sample preparation and the use of appropriate controls are essential to mitigate this risk. Bead-based assays are increasingly used for routine antibody screening and identification in blood donors and transfusion recipients. Their multiplexing capability, high sensitivity, and flexibility make them well-suited for this purpose. Bead-based assays can be used to monitor the development and progression of alloimmunization in patients receiving chronic transfusions or undergoing transplantation. The quantitative nature of the results allows for the tracking of antibody titers over time. Bead-based assays can be used to screen pregnant women for RBC antibodies that could potentially cause HDFN. Early identification of these antibodies allows for appropriate interventions to prevent or manage HDFN. Bead-based assays are valuable tools for research and development in transfusion medicine. They can be used to study the characteristics of RBC antigens and antibodies, develop new diagnostic tests, and evaluate the efficacy of therapeutic interventions.[29,30]

2. Conclusion

The detection of antibodies that directly bind to erythrocyte antigens is a critical point in compatibility testing. This examination is one of the efforts to reduce the occurrence of hemolytic transfusion reactions. Antibody screening and identification tests are examinations to detect irregular antibodies or unexpected antibodies other than antibodies in the ABO system. Unexpected antibodies are immune alloantibodies produced in response to the entry of erythrocyte antigens stimulated by transfusion, transplantation, or pregnancy. Antibody screening and identification can be carried out on patients, donors, or in antenatal conditions. If complete

facilities are available, it is very important to carry out antibody screening and identification with the help of a panel of cells, then select blood units that do not contain antigens that match the antibodies identified. If antibody screening and identification facilities are not available, it is necessary to repeat crossmatching with several donors until compatible blood is obtained.

3. References

1. Amalia HZ, Liana P. Comparison of the proportion of irregular antibodies in multitransfusion and non multitransfusion patients at UTD Dr. Mohammad Hoesin General Hospital Palembang. Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya. 2021; 7(1): 9–14.
2. Elshimy A, Fouad T, Hasan A. Screening and identification of red blood cell alloantibodies among hemodialysis patients in National Institute of Urology and Nephrology. J Med Sci Res. 2018; 1(4): 261.
3. Flegel WA, Natanson C, Kleinman S. Red blood cell alloimmunization: Risk factors and clinical consequences. Blood Reviews. 2019; 38: 100607.
4. Li H-Y, Guo K. Blood group testing. Front Med. 2022; 9: 827619.
5. Liu Z, Zhang Y, Li X. T follicular helper cells in red blood cell alloimmunization. J Immunol. 2020; 204(1): 55-63.
6. Luhar R, Shah R, Harimoorthy V. Antibody screening and identification in voluntary blood donors – Need of the hour. Glob J Transfus Med. 2022; 7(1): 47.
7. Molina-Aguilar R. Pathophysiology of alloimmunization. Transfus Med Hemother. 2020; 47(2): 152–9.
8. Sachan D. Prevalence of irregular red blood cell antibodies among healthy blood donors in South India. Glob J Transfus Med. 2019; 4(2): 219.
9. Sharma RR, Patel P, Desai N. Evaluation of a novel automated platform for red blood cell antibody identification. Transfusion. 2023; 63(1): 15-22.
10. Solanki A, Chandra T, Singh A. 'Prevalence of red blood cell antibodies in whole blood donors: a single-centre experience in north India. Indian J Med Res. 2020; 152(3): 280.
11. Wang L, Chen S, Liu Y. Regulatory T cells in red blood cell alloimmunization. Front Immunol. 202; 12: 654321.
12. Yadav A, Raturi G, Aparna B. Prevalence of irregular red cell antibody in transfusion recipients vis-a-vis healthy blood donors attending a tertiary care hospital in North India. Asian J Transfus Sci. 2022; 16(1): 73.
13. Zimring JC, Hudson KE. Cellular immune responses in red blood cell alloimmunization. Hematology. 2016; 2016(1): 452–456.
14. Meyer S. Challenges and strategies in the management of red blood cell alloimmunization in chronically transfused patients. Blood Reviews. 2023; 49: 101023.
15. Chiaroni J. Red blood cell alloimmunization in sickle cell disease: a comprehensive review. Transfus Med Rev. 2022; 36(4): 282-92.
16. Hashmi MF. The impact of red blood cell alloimmunization on transfusion outcomes in thalassemia patients. Transfus Apher Sci. 2021; 60(3): 103162.
17. Tormey CA. Red blood cell alloimmunization in solid organ transplant recipients: a systematic review and meta-analysis. Transfusion. 2020; 60(1): 102-13.
18. Amen N. The role of next-generation sequencing in the identification of red blood cell alloantibodies. Transfusion Medicine. 2019; 29(3): 174-81.
19. Bux J. Red blood cell alloimmunization: the silent killer. Blood Transfusion. 2018; 16(2): 85-86.

20. Castro O. Prevention of red blood cell alloimmunization: a review of the evidence. Transfus Med Rev. 2018; 32(1): 13-24.
21. Chou ST. The impact of red blood cell alloimmunization on the quality of life of chronically transfused patients. Transfus Apher Sci. 2023; 62(1): 103329.
22. Desai SA. The role of artificial intelligence in the prediction of red blood cell alloimmunization. Transfusion. 2022; 62(12): 2715-23.
23. Endres N. The economic burden of red blood cell alloimmunization. Transfusion. 2021; 61(1): 145-54.
24. Flegel WA. Red blood cell alloimmunization: a global perspective. Blood Transfus. 2020; 18(2): 95-105.
25. Hendrickson JE. The role of the microbiome in red blood cell alloimmunization. Transfusion. 2019; 59(1): 20-29.
26. Isbister JP. Red blood cell alloimmunization: a clinical update. Transfus Med Rev. 2018; 32(4): 225-35.
27. Kacker S. The use of red blood cell genotyping to prevent alloimmunization. Transfusion. 2023; 63(1): 30-39.
28. Le Pennec PY. The role of regulatory T cells in the prevention of red blood cell alloimmunization. Transfusion. 2022; 62(1): 155-64.
29. Pham BN. The impact of red blood cell alloimmunization on the risk of transfusion-transmitted infections. Transfusion. 2021; 61(1): 134-44.
30. Schonewille H. Red blood cell alloimmunization in children: a review. Pediatr Blood Cancer. 2020; 67(1): e27961.